Crossmark

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors

Crossref DOI link: https://doi.org/10.1038/s43018-024-00840-y

Published Online: 2024-10-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Burr, Risa

Leshchiner, Ignaty https://orcid.org/0000-0001-8942-9265
Costantino, Christina L.

Blohmer, Martin

Sundaresan, Tilak

Cha, Justin https://orcid.org/0000-0001-6026-2211
Seeger, Karsen

Guay, Sara

Danysh, Brian P.

Gore, Ira

Jacobs, Raquel A.

Slowik, Kara

Utro, Filippo https://orcid.org/0000-0003-3226-7642
Rhrissorrakrai, Kahn

Levovitz, Chaya https://orcid.org/0000-0002-9251-2294
Barth, Jaimie L.

Dubash, Taronish

Chirn, Brian

Parida, Laxmi https://orcid.org/0000-0002-7872-5074
Sequist, Lecia V.

Lennerz, Jochen K.

Mino-Kenudson, Mari

Maheswaran, Shyamala

Naxerova, Kamila https://orcid.org/0000-0001-7744-5110
Getz, Gad https://orcid.org/0000-0002-0936-0753
Haber, Daniel A. https://orcid.org/0000-0003-1378-6551
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | National Institutes of Health (R01CA137008)

U.S. Department of Health & Human Services | National Institutes of Health (5F32CA221103)

U.S. Department of Health & Human Services | National Institutes of Health (1P50CA265826)

U.S. Department of Health & Human Services | National Institutes of Health (5R01CA137008)

U.S. Department of Health & Human Services | National Institutes of Health (R01CA240317)

U.S. Department of Health & Human Services | National Institutes of Health (R37CA225655)

Howard Hughes Medical Institute

Charles A. King Trust

Lungstrong Foundation The Landry Family

IBM Research
License Information

Text and Data Mining valid from 2024-10-15

Version of Record valid from 2024-10-15
More Information

Article History

Received: 5 April 2023

Accepted: 10 September 2024

First Online: 15 October 2024

Competing interests

: L.V.S. has institutional research funding from AstraZeneca, Novartis and Delfi Diagnostics and has received consulting fees from AstraZeneca, Janssen, Pfizer and Genentech. I.L. serves as a consultant for PACT Pharma Inc., has stock, is on the board and serves as a consultant for ennov1 LLC, and is on the board and holds equity in Nord Bio, Inc. G.G. receives research funds from IBM, Pharmacyclics/Abbvie, Bayer, Genentech and Ultima Genomics, and is also an inventor on patent applications filed by the Broad Institute related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSIDetect and MinumuMM-seq. He is a founder and consultant and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in, PreDICTA Biosciences. M.M.-K. has served as a compensated consultant for AstraZeneca, Pfizer, Repare, Sanofi, AbbVie and Daiichi Sankyo and has received royalties from Elsevier. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below